? OVERALL The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an ?exceptional? overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.

Public Health Relevance

The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research, education and community outreach and engagement as research conducted within the five OSUCCC Programs focuses on high priority cancers for the OSUCCC including lung, breast, colorectal, prostate, endometrial, cervical cancer, thyroid, and leukemia, as well as tobacco use, obesity and HPV vaccination. Screening and outreach activities are provided to the populations across the lifespan that we serve, especially those with higher burden of being diagnosd with cancer, such as racial/ethnic minorities and other underserved populations (e.g., rural, LGBTQ+, Appalachian) through targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, and addressing policy issues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089990
Study Section
Subcommittee H - Clinical Groups (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2021-01-25
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Surgery
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Koster, Roelof; Panagiotou, Orestis A; Wheeler, William A et al. (2018) Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142:1594-1601

Showing the most recent 10 out of 2602 publications